Ipca: ₹16.90 Cr Mahad Sale Above Written-Down Value
**View: Positive, but a relatively small transaction.** Ipca Laboratories (IPCALAB) plans to close its Mahad drug intermediates unit and monetise the property above its written-down value, while consolidating manufacturing at other facilities. **Transaction details** - The company will sell/transfer leasehold land and old factory buildings at Mahad, Maharashtra, to ICMC Corporation Ltd for **₹16.90 Cr**, against a current written-down value of **₹13.21 Cr**. - The property includes approximately **25,138 sq. metres of land** and **11,913 sq. metres of old factory buildings, structures and sheds**. - ICMC operates in the micronutrient fertiliser business and is neither part of the promoter group nor a related party. **Operational transition** Production of drug intermediates has already been transferred to other manufacturing facilities. Plant and machinery will also be shifted to other company units. **Timeline and caveats** Completion is expected **on or before 31 March 2027**, subject to MIDC approval for the leasehold transfer. The final financial benefit will depend on associated costs and the accounting treatment.



















